10/16/2020
6:43 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/14/2020
10:20 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/14/2020
10:11 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/13/2020
11:13 AM | GlaxoSmithKline (Subject)
NEW YORK STOCK EXCHANGE LLC (Filed by)
| Form 25-NSE
| |
10/13/2020
10:04 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/13/2020
9:17 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/13/2020
9:17 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/13/2020
8:39 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/13/2020
8:26 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/07/2020
9:33 AM | GlaxoSmithKline (Filer)
| Form CERT
| |
|
10/01/2020
1:52 PM | GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
| Form 8-A12B
| |
10/01/2020
1:50 PM | GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/01/2020
11:32 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/30/2020
9:56 AM | GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
| Form 424B2
| |
09/28/2020
3:24 PM | GLAXOSMITHKLINE CAPITAL PLC (Filed by)
GlaxoSmithKline (Subject)
| Form FWP
| |
09/28/2020
3:22 PM | GLAXOSMITHKLINE CAPITAL PLC (Subject)
GlaxoSmithKline (Filed by)
| Form FWP
| |
09/28/2020
8:30 AM | GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
GlaxoSmithKline (Filer)
| Form 424B2
| |
09/28/2020
7:53 AM | GLAXOSMITHKLINE CAPITAL PLC (Filer)
GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/22/2020
12:46 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/18/2020
11:04 AM | BICYCLE THERAPEUTICS plc (Issuer)
GlaxoSmithKline (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/11/2020
11:49 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/10/2020
5:17 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/09/2020
9:57 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/09/2020
7:21 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/03/2020
5:21 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/01/2020
10:08 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/24/2020
3:12 PM | CureVac N.V. (Subject)
GlaxoSmithKline (Filed by)
| Form SC 13G
| |
08/13/2020
6:03 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/06/2020
5:21 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/03/2020
6:05 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/30/2020
7:56 PM | GENOCEA BIOSCIENCES, INC. (Issuer)
GlaxoSmithKline (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/29/2020
11:01 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/29/2020
9:34 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/29/2020
6:09 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/28/2020
10:19 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/24/2020
8:06 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/22/2020
4:23 PM | GlaxoSmithKline (Filed by)
Nkarta, Inc. (Subject)
| Form SC 13D
| |
07/22/2020
3:18 PM | GlaxoSmithKline (Reporting)
Pandion Therapeutics, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/20/2020
6:36 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/16/2020
8:52 PM | GlaxoSmithKline (Reporting)
Pandion Therapeutics, Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
07/16/2020
7:13 PM | GlaxoSmithKline (Reporting)
Nkarta, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/15/2020
6:20 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/15/2020
5:30 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/14/2020
3:48 PM | GlaxoSmithKline (Reporting)
Nkarta, Inc. (Issuer)
| Form 3/A
| |
07/14/2020
12:59 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/13/2020
12:27 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2020
4:26 PM | CRISPR Therapeutics AG (Subject)
GlaxoSmithKline (Filed by)
| Form SC 13D/A
| |
07/10/2020
12:05 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2020
11:25 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/10/2020
11:17 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/09/2020
7:58 PM | GlaxoSmithKline (Reporting)
Nkarta, Inc. (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
07/01/2020
7:46 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/29/2020
5:50 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/22/2020
4:29 PM | GlaxoSmithKline (Reporting)
Theravance Biopharma, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/22/2020
4:13 PM | GlaxoSmithKline (Filed by)
Theravance Biopharma, Inc. (Subject)
| Form SC 13D/A
| |
06/19/2020
9:55 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/18/2020
11:41 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/18/2020
7:46 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/16/2020
7:43 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/11/2020
11:29 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/09/2020
8:56 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/04/2020
4:03 PM | GlaxoSmithKline (Filed by)
Spero Therapeutics, Inc. (Subject)
| Form SC 13D/A
| |
06/01/2020
11:23 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/26/2020
4:06 PM | GlaxoSmithKline (Filed by)
Turning Point Therapeutics, Inc. (Subject)
| Form SC 13D/A
| |
05/26/2020
3:17 PM | GlaxoSmithKline (Reporting)
Turning Point Therapeutics, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/26/2020
6:32 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/21/2020
4:21 PM | GlaxoSmithKline (Reporting)
Progyny, Inc. (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/19/2020
12:38 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/18/2020
5:50 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/13/2020
12:28 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/12/2020
5:23 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/11/2020
12:51 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/07/2020
10:31 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/06/2020
12:05 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/04/2020
12:01 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/04/2020
11:13 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/01/2020
12:42 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/30/2020
7:14 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/29/2020
7:21 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/16/2020
11:20 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/16/2020
9:36 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/16/2020
9:28 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/14/2020
12:46 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/14/2020
7:35 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/09/2020
7:50 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/06/2020
7:55 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/01/2020
8:43 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/01/2020
7:05 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/24/2020
5:27 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/20/2020
9:34 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/18/2020
8:23 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/11/2020
1:02 PM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/09/2020
11:49 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/09/2020
6:30 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/04/2020
10:17 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/02/2020
6:16 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/28/2020
3:48 PM | GENOCEA BIOSCIENCES, INC. (Subject)
GlaxoSmithKline (Filed by)
| Form SC 13G/A
| |
02/21/2020
7:23 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/20/2020
10:16 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/20/2020
8:44 AM | GlaxoSmithKline (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
